Cargando…
Focal lesions following intracerebral gene therapy for mucopolysaccharidosis IIIA
OBJECTIVE: Mucopolysaccharidosis type IIIA (MPSIIIA) caused by recessive SGSH variants results in sulfamidase deficiency, leading to neurocognitive decline and death. No disease‐modifying therapy is available. The AAVance gene therapy trial investigates AAVrh.10 overexpressing human sulfamidase (LYS...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10270249/ https://www.ncbi.nlm.nih.gov/pubmed/37165777 http://dx.doi.org/10.1002/acn3.51772 |
_version_ | 1785059293790208000 |
---|---|
author | Bugiani, Marianna Abbink, Truus E. M. Edridge, Arthur W. D. van der Hoek, Lia Hillen, Anne E. J. van Til, Niek P. Hu‐A‐Ng, Gino V. Breur, Marjolein Aiach, Karen Drevot, Philippe Hocquemiller, Michaël Laufer, Ralph Wijburg, Frits A. van der Knaap, Marjo S. |
author_facet | Bugiani, Marianna Abbink, Truus E. M. Edridge, Arthur W. D. van der Hoek, Lia Hillen, Anne E. J. van Til, Niek P. Hu‐A‐Ng, Gino V. Breur, Marjolein Aiach, Karen Drevot, Philippe Hocquemiller, Michaël Laufer, Ralph Wijburg, Frits A. van der Knaap, Marjo S. |
author_sort | Bugiani, Marianna |
collection | PubMed |
description | OBJECTIVE: Mucopolysaccharidosis type IIIA (MPSIIIA) caused by recessive SGSH variants results in sulfamidase deficiency, leading to neurocognitive decline and death. No disease‐modifying therapy is available. The AAVance gene therapy trial investigates AAVrh.10 overexpressing human sulfamidase (LYS‐SAF302) delivered by intracerebral injection in children with MPSIIIA. Post‐treatment MRI monitoring revealed lesions around injection sites. Investigations were initiated in one patient to determine the cause. METHODS: Clinical and MRI details were reviewed. Stereotactic needle biopsies of a lesion were performed; blood and CSF were sampled. All samples were used for viral studies. Immunohistochemistry, electron microscopy, and transcriptome analysis were performed on brain tissue of the patient and various controls. RESULTS: MRI revealed focal lesions around injection sites with onset from 3 months after therapy, progression until 7 months post therapy with subsequent stabilization and some regression. The patient had transient slight neurological signs and is following near‐normal development. No evidence of viral or immunological/inflammatory cause was found. Immunohistochemistry showed immature oligodendrocytes and astrocytes, oligodendrocyte apoptosis, strong intracellular and extracellular sulfamidase expression and hardly detectable intracellular or extracellular heparan sulfate. No activation of the unfolded protein response was found. INTERPRETATION: Results suggest that intracerebral gene therapy with local sulfamidase overexpression leads to dysfunction of transduced cells close to injection sites, with extracellular spilling of lysosomal enzymes. This alters extracellular matrix composition, depletes heparan sulfate, impairs astrocyte and oligodendrocyte function, and causes cystic white matter degeneration at the site of highest gene expression. The AAVance trial results will reveal the potential benefit–risk ratio of this therapy. |
format | Online Article Text |
id | pubmed-10270249 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102702492023-06-16 Focal lesions following intracerebral gene therapy for mucopolysaccharidosis IIIA Bugiani, Marianna Abbink, Truus E. M. Edridge, Arthur W. D. van der Hoek, Lia Hillen, Anne E. J. van Til, Niek P. Hu‐A‐Ng, Gino V. Breur, Marjolein Aiach, Karen Drevot, Philippe Hocquemiller, Michaël Laufer, Ralph Wijburg, Frits A. van der Knaap, Marjo S. Ann Clin Transl Neurol Research Articles OBJECTIVE: Mucopolysaccharidosis type IIIA (MPSIIIA) caused by recessive SGSH variants results in sulfamidase deficiency, leading to neurocognitive decline and death. No disease‐modifying therapy is available. The AAVance gene therapy trial investigates AAVrh.10 overexpressing human sulfamidase (LYS‐SAF302) delivered by intracerebral injection in children with MPSIIIA. Post‐treatment MRI monitoring revealed lesions around injection sites. Investigations were initiated in one patient to determine the cause. METHODS: Clinical and MRI details were reviewed. Stereotactic needle biopsies of a lesion were performed; blood and CSF were sampled. All samples were used for viral studies. Immunohistochemistry, electron microscopy, and transcriptome analysis were performed on brain tissue of the patient and various controls. RESULTS: MRI revealed focal lesions around injection sites with onset from 3 months after therapy, progression until 7 months post therapy with subsequent stabilization and some regression. The patient had transient slight neurological signs and is following near‐normal development. No evidence of viral or immunological/inflammatory cause was found. Immunohistochemistry showed immature oligodendrocytes and astrocytes, oligodendrocyte apoptosis, strong intracellular and extracellular sulfamidase expression and hardly detectable intracellular or extracellular heparan sulfate. No activation of the unfolded protein response was found. INTERPRETATION: Results suggest that intracerebral gene therapy with local sulfamidase overexpression leads to dysfunction of transduced cells close to injection sites, with extracellular spilling of lysosomal enzymes. This alters extracellular matrix composition, depletes heparan sulfate, impairs astrocyte and oligodendrocyte function, and causes cystic white matter degeneration at the site of highest gene expression. The AAVance trial results will reveal the potential benefit–risk ratio of this therapy. John Wiley and Sons Inc. 2023-05-11 /pmc/articles/PMC10270249/ /pubmed/37165777 http://dx.doi.org/10.1002/acn3.51772 Text en © 2023 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Articles Bugiani, Marianna Abbink, Truus E. M. Edridge, Arthur W. D. van der Hoek, Lia Hillen, Anne E. J. van Til, Niek P. Hu‐A‐Ng, Gino V. Breur, Marjolein Aiach, Karen Drevot, Philippe Hocquemiller, Michaël Laufer, Ralph Wijburg, Frits A. van der Knaap, Marjo S. Focal lesions following intracerebral gene therapy for mucopolysaccharidosis IIIA |
title | Focal lesions following intracerebral gene therapy for mucopolysaccharidosis IIIA
|
title_full | Focal lesions following intracerebral gene therapy for mucopolysaccharidosis IIIA
|
title_fullStr | Focal lesions following intracerebral gene therapy for mucopolysaccharidosis IIIA
|
title_full_unstemmed | Focal lesions following intracerebral gene therapy for mucopolysaccharidosis IIIA
|
title_short | Focal lesions following intracerebral gene therapy for mucopolysaccharidosis IIIA
|
title_sort | focal lesions following intracerebral gene therapy for mucopolysaccharidosis iiia |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10270249/ https://www.ncbi.nlm.nih.gov/pubmed/37165777 http://dx.doi.org/10.1002/acn3.51772 |
work_keys_str_mv | AT bugianimarianna focallesionsfollowingintracerebralgenetherapyformucopolysaccharidosisiiia AT abbinktruusem focallesionsfollowingintracerebralgenetherapyformucopolysaccharidosisiiia AT edridgearthurwd focallesionsfollowingintracerebralgenetherapyformucopolysaccharidosisiiia AT vanderhoeklia focallesionsfollowingintracerebralgenetherapyformucopolysaccharidosisiiia AT hillenanneej focallesionsfollowingintracerebralgenetherapyformucopolysaccharidosisiiia AT vantilniekp focallesionsfollowingintracerebralgenetherapyformucopolysaccharidosisiiia AT huangginov focallesionsfollowingintracerebralgenetherapyformucopolysaccharidosisiiia AT breurmarjolein focallesionsfollowingintracerebralgenetherapyformucopolysaccharidosisiiia AT aiachkaren focallesionsfollowingintracerebralgenetherapyformucopolysaccharidosisiiia AT drevotphilippe focallesionsfollowingintracerebralgenetherapyformucopolysaccharidosisiiia AT hocquemillermichael focallesionsfollowingintracerebralgenetherapyformucopolysaccharidosisiiia AT lauferralph focallesionsfollowingintracerebralgenetherapyformucopolysaccharidosisiiia AT wijburgfritsa focallesionsfollowingintracerebralgenetherapyformucopolysaccharidosisiiia AT vanderknaapmarjos focallesionsfollowingintracerebralgenetherapyformucopolysaccharidosisiiia |